Combining Quinidine and Epirubicin for Advanced Breast Cancer
Author Information
Author(s): R.D Jones, D.J. Kerr, A.N. Harnett, E.M. Rankin, S. Ray, S.B. Kaye
Primary Institution: Beatson Oncology Centre, Western Infirmary, Glasgow
Hypothesis
Can quinidine improve the effectiveness of epirubicin in treating advanced breast cancer?
Conclusion
The combination of quinidine and epirubicin appears feasible and does not increase toxicity compared to epirubicin alone.
Supporting Evidence
- Three patients treated with quinidine 1 g b.d. experienced toxicity.
- Two out of eight patients treated with quinidine 500 mg b.d. had toxicity.
- Twenty patients received quinidine 250 mg b.d. with minimal toxicity observed.
Takeaway
Doctors tested a new drug called quinidine with another drug, epirubicin, to see if it helps treat breast cancer better without making patients feel worse.
Methodology
A pilot study involving 31 patients with advanced breast cancer receiving varying doses of quinidine alongside epirubicin.
Limitations
The study was a pilot with a small sample size and did not assess long-term outcomes.
Participant Demographics
Patients were mostly women with a median age of 56 years, and all had locally advanced or metastatic breast cancer.
Want to read the original?
Access the complete publication on the publisher's website